Arcadia Biosciences (RKDA) M&A Announcement summary
Event summary combining transcript, slides, and related documents.
M&A Announcement summary
11 Jan, 2026Deal rationale and strategic fit
Culminates an 18-month strategic review, with Arcadia streamlining operations and asset sales since July 2023, concluding that a business combination with Roosevelt offers the best value for shareholders.
The combination leverages Roosevelt's oil and gas expertise and Arcadia's public company platform, focusing on Roosevelt's large-scale CCUS and EOR projects in the Permian Basin.
Zola Coconut Water, a growing Arcadia brand, will continue under Roosevelt ownership, with select Arcadia team members assisting operations.
Financial terms and conditions
All-stock transaction: Arcadia will issue approximately 12,284,475 shares to Roosevelt partners for 100% of Roosevelt’s equity.
Roosevelt equity owners will hold about 90% of the combined company’s shares, with Arcadia shareholders retaining about 10%, subject to adjustments.
Transaction expected to close in Q1 2025 or later, pending regulatory and shareholder approvals.
Integration plans and timeline
The company will be renamed Roosevelt Resources, Inc. and trade on NASDAQ under a new symbol.
Roosevelt’s management team will lead the combined entity, with some Arcadia personnel supporting ongoing operations.
The board will include three Roosevelt directors, one Arcadia director, and one independent director.
Steps include SEC filing (S-4), proxy statement distribution, shareholder meeting, and closing.
Latest events from Arcadia Biosciences
- Q2 net income up 30% on asset sales and 42% Zola growth, but liquidity remains a concern.RKDA
Q2 20241 Feb 2026 - Registering 1.67M shares for resale, with proceeds for working capital amid going concern risk.RKDA
Registration Filing28 Jan 2026 - Q3 revenue up 18% with Zola sales surging 55% and net loss sharply reduced.RKDA
Q3 202414 Jan 2026 - Zola sales surged 46% in 2024, fueling growth as the business streamlined and prepared for a major transaction.RKDA
Q4 202426 Dec 2025 - Q1 2025 net income hit $2.6M as Zola sales soared, but liquidity risks persist.RKDA
Q1 202524 Nov 2025 - Proxy covers director elections, executive pay, auditor ratification, and governance practices.RKDA
Proxy Filing19 Nov 2025 - Zola sales up 26% YTD, margins strong, but liquidity and merger timing risks remain.RKDA
Q3 20257 Nov 2025 - Revenue rose 11% but a $4.5M credit loss and liquidity issues led to a net loss.RKDA
Q2 202514 Aug 2025